Another failure for Sumitomo Dainippon's napabucasin, now in colorectal cancer
Shares of Japanese drugmaker Sumitomo Dainippon Pharma (TYO: 4506) closed down more than 8% at 1,724 yen today, after it announced the top-line results that the Phase III CanStem303C study evaluating the safety and efficacy of investigational anticancer agent napabucasin (BI608) failed to reach the primary endpoints.
The safety profile was consistent with that in the previous clinical studies of napabucasin. The detailed results of the study will be presented at scientific meetings in the future.
The company said it is currently reviewing its consolidated financial forecasts for the fiscal year ending March 2021 based on the results of this study and its recent performance trends and will promptly make further announcements if it revised the financial forecasts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze